Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492820 | 0.89 | ROCK2 (0.57) | ROCK2ROCK1POLBMAPK1KMT2A | |
| SCHEMBL5700207 | 0.86 | KMT2A (0.55) | ROCK2ROCK1NPC1NR4A1KMT2A | |
| SCHEMBL1040762 | 0.83 | NR4A1 (0.62) | NPC1POLBNR4A1MAPK1SRD5A2 | |
| SCHEMBL9261793 | 0.83 | KMT2A (0.50) | ROCK2ROCK1NPC1POLBMAPK1 | |
| SCHEMBL4859699 | 0.82 | MAPT (0.49) | ROCK2ROCK1NPC1POLBLMNA | |
| SCHEMBL9259850 | 0.82 | JAK2 (0.50) | ROCK2ROCK1NPC1POLBSRD5A2 | |
| SCHEMBL7087043 | 0.80 | ALDH1A1 (0.50) | ROCK2ROCK1NPC1POLBKMT2A | |
| SCHEMBL8852563 | 0.78 | NPC1 (0.58) | NPC1POLBNR4A1MAPK1SRD5A2 | |
| SCHEMBL1156055 | 0.77 | LMNA (0.63) | MAPK1SRD5A2KMT2ANT5ELMNA | |
| SCHEMBL3481832 | 0.75 | JAK2 (0.59) | NPC1POLBSRD5A2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2328895-A1 | NEW COMPOUNDS II | Proximagen Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195992-A1 | NEW COMPOUNDS II | SSB, NFKBIA, ALOX15B | ROCK2 1641/4885ROCK1 2138/4885NPC1 639/4885 |
| US-20140107150-A1 | New Compounds II | SSB, NFKBIA, ALOX15B | ROCK2 1641/4885ROCK1 2138/4885NPC1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.